InMed Pharmaceuticals Inc. INM · Stock Open InMed Pharmaceuticals Inc. in new tab
InMed Pharmaceuticals Inc. Analysis (INM)
Is InMed Pharmaceuticals Inc. a good investment? InMed Pharmaceuticals Inc. (INM) is currently trading at 1.46 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.02. This relatively low multiple may signal that InMed Pharmaceuticals Inc. is undervalued compared to historical market norms.
Earnings Schedule: InMed Pharmaceuticals Inc. is expected to release its next earnings report on Sept. 18, 2026. The market consensus estimate for Forward EPS is -6.25.
Investor FAQ
Does InMed Pharmaceuticals Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is InMed Pharmaceuticals Inc.?
InMed Pharmaceuticals Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Sept. 18, 2026. The company currently has a trailing EPS of -1.47.
Company Profile
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
| Split Date | Split Ratio to 1 |
|---|---|
| July 6, 2020 | 0.030000 |
| Sept. 7, 2022 | 0.040000 |
| Nov. 14, 2024 | 0.050000 |
Community Discussion